ADHD and Addiction: Managing Stimulant Medications During Rehab
ADHD and substance use disorders co-occur at high rates. Studies consistently show that 15 to 25% of adults with substance use disorders also have ADHD, and people with ADHD are 2 to 3 times more likely to develop a substance use disorder compared to the general population. The relationship is not coincidental: ADHD involves the same dopamine signaling pathways that substances hijack, and many people with undiagnosed or undertreated ADHD use substances (particularly stimulants and alcohol) as self-medication.
This creates a clinical puzzle during addiction treatment: how do you treat a condition (ADHD) that often requires stimulant medication when the patient is in treatment for substance use disorder?
The Medication Dilemma
Stimulant medications for ADHD (methylphenidate, amphetamine salts) are Schedule II controlled substances with documented abuse potential. In a treatment setting, the clinical team must weigh competing risks:
Risk-Benefit Balance: Stimulants During Treatment
| Factor | Risk of Continuing Stimulants | Risk of Stopping Stimulants |
|---|---|---|
| Relapse | Stimulant access may trigger misuse or diversion | Untreated ADHD impairs executive function, increasing impulsivity and relapse risk |
| Therapy engagement | N/A | Patients with untreated ADHD struggle to focus in therapy sessions, retain psychoeducation material and complete assignments |
| Sleep and stability | Stimulants can disrupt sleep, which is already fragile in early recovery | Sleep may improve initially but ADHD-related restlessness returns |
| Diagnostic clarity | Continued stimulant use masks whether ADHD symptoms persist in sobriety | Withdrawal observation period (2-4 weeks) allows accurate reassessment |
How Programs Typically Handle It
There is no universal protocol. Programs fall on a spectrum:
| Approach | How It Works | Best Suited For |
|---|---|---|
| Immediate discontinuation + reassessment | All stimulants stopped at admission; ADHD reassessed after 2-4 weeks of sobriety; non-stimulant medication started if symptoms persist | Programs focused on complete abstinence; patients whose ADHD diagnosis is uncertain; stimulant use disorder |
| Transition to non-stimulant | Stimulants tapered and replaced with non-stimulant ADHD medication (atomoxetine, guanfacine, bupropion) within the first week | Most programs; provides ADHD symptom management without abuse risk |
| Controlled continuation | Stimulant medication continued under strict supervision (medication administered by staff, not self-administered; extended-release only; daily monitoring) | Programs with strong medical oversight; patients with well-documented ADHD who are not misusing their stimulant; non-stimulant primary substance use disorder |
| Vyvanse protocol | Lisdexamfetamine (Vyvanse) specifically continued due to its lower abuse potential (prodrug requiring GI metabolism; cannot be snorted or injected effectively) | Evidence-based compromise; Vyvanse has the best safety profile among stimulants in addiction-treated populations |
Non-Stimulant ADHD Medications
When stimulants are discontinued or not appropriate, several non-stimulant options provide meaningful ADHD symptom management:
| Medication | Mechanism | Effectiveness vs Stimulants | Notes for Addiction Treatment |
|---|---|---|---|
| Atomoxetine (Strattera) | Norepinephrine reuptake inhibitor | Moderate (effect size 0.6 vs 0.9 for stimulants) | No abuse potential; takes 2-4 weeks for full effect; FDA-approved for ADHD |
| Guanfacine ER (Intuniv) | Alpha-2 agonist | Moderate | Helps with impulsivity and emotional dysregulation; can lower blood pressure; useful as adjunct |
| Bupropion (Wellbutrin) | Norepinephrine/dopamine reuptake inhibitor | Mild to moderate for ADHD | Also treats depression; reduces cigarette cravings; avoid in patients with seizure history or eating disorders |
| Viloxazine (Qelbree) | Norepinephrine reuptake modulator | Moderate | FDA-approved for ADHD in adults (2023); newer option with growing evidence |
What Integrated Treatment Looks Like
A program that genuinely addresses ADHD and addiction together, rather than treating one and ignoring the other, includes:
- Comprehensive neuropsychological assessment after 2 to 4 weeks of sobriety, using standardized diagnostic tools (Conners Adult ADHD Rating Scales, continuous performance testing)
- Cognitive-behavioral therapy adapted for ADHD: Shorter sessions (30 to 45 minutes versus 50 to 60), more structured exercises, written summaries of key points, visual aids and checklists
- Skills training: Organization systems, time management, emotional regulation techniques that address the executive function deficits driving both conditions
- Medication management by a psychiatrist experienced in both ADHD and addiction (not all addiction psychiatrists are comfortable managing ADHD, and not all ADHD specialists understand addiction)
- Psychoeducation on the ADHD-addiction link, self-medication patterns and how to manage ADHD in recovery without substances
Comparing rehab destinations beyond Colombia? Country-by-country treatment comparisons at rehabcountries.com.
Exploring other medical procedures in Colombia? Start at colombiamedical.co for the full network.
Confidential Questions About Treatment in Colombia?
We provide confidential guidance on accredited treatment programs in Colombia.
Message Us on WhatsAppFrequently Asked Questions
Will rehab take away my ADHD medication?
Not necessarily, but it depends on the medication and the program's clinical assessment. Stimulant medications (Adderall, Ritalin, Vyvanse) present a dilemma because they have abuse potential. Many programs transition patients to non-stimulant alternatives during treatment, then reassess after stabilization. Some programs continue stimulants under strict medical supervision if the ADHD diagnosis is confirmed and the stimulant is not part of the substance use pattern. Ask the program directly about their protocol before enrolling.
Can ADHD be misdiagnosed in people with substance use disorders?
Yes, and this is common. Substance intoxication and withdrawal can mimic ADHD symptoms (difficulty concentrating, impulsivity, restlessness, disorganization). Studies suggest that up to 30% of ADHD diagnoses in patients with active substance use disorders may not be confirmed after a period of abstinence. This is why many programs reassess ADHD after 2 to 4 weeks of sobriety using standardized diagnostic tools rather than relying on a prior diagnosis alone.